Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating
Goldman Sachs initiated coverage on Madrigal Pharmaceuticals (MDGL) with a Buy rating and $704 price target. The company's Rezdiffra drug generated $1.3B in 12-month revenue with 91% gross margins. Q2 2026 revenue grew 71% YoY to $364.3M, exceeding estimates. Analysts maintain positive ratings despite net losses and rising expenses.
How this was made
The 30-second read
Why it matters
The new coverage adds a bullish catalyst that could attract fresh capital, but execution risk remains.
Market read
Analyst initiation is a notable catalyst for MDGL, potentially influencing biotech sector sentiment.
What to watch
Potential regulatory or data‑delay risks could temper upside.
Background
Madrigal Pharmaceuticals recently reported strong Q2 revenue growth and high gross margins for its NASH drug Rezdiffra.
Ticker impact
Goldman Sachs initiated coverage with a Buy rating and a $704 price target for Madrigal Pharmaceuticals.
Potential upside toward the new target if buying pressure follows.
Buy rating and elevated target represent fresh, bullish view from a top-tier bank.
Market effects
May boost sentiment in the NASH/biotech therapeutic space.
Limited to US biotech investors.
Minor global effect, primarily US market.
Counterpoint
The high valuation may be premature given the company's ongoing net losses.
Key entities
- AnalystGoldman Sachs
Initiated coverage with a Buy rating.
- CompanyMadrigal Pharmaceuticals
Biotech firm developing NASH therapies.
